Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
| Status: | Terminated |
|---|---|
| Conditions: | Cardiology, Ocular |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Ophthalmology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 10/14/2017 |
| Start Date: | September 2008 |
| End Date: | March 2010 |
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus
(rapamycin) formulation via different injection routes in patients with treatment-naive
sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
(rapamycin) formulation via different injection routes in patients with treatment-naive
sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
Inclusion Criteria include, but are not limited to:
- Diagnosed with sub-foveal choroidal neovascularization secondary to age-related
macular degeneration
- Visual acuity of 20/50 to 20/200 in study eye
Exclusion Criteria:
- Any other ocular disease that could compromise vision in the study eye
- History of any prior treatment for choroidal neovascularization in the study eye
- Presence of other causes of choroidal neovascularization other than secondary to
age-related macular degeneration
We found this trial at
1
site
Click here to add this to my saved trials
